Simultaneous determination of benazepril hydrochloride and benazeprilat in plasma by high-performance liquid chromatography/electrospray-mass spectrometry

J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 25;814(2):303-8. doi: 10.1016/j.jchromb.2004.10.047.

Abstract

An analytical method for simultaneous determination of benazepril and its active metabolite, benazeprilat, in human plasma by high-performance liquid chromatography/electrospray-mass spectrometry was developed and validated. Rutaecarpine was selected as the internal standard. The separation was achieved on a C(18) column with acetonitrile and aqueous solution (0.1% formic acid) as mobile phase with a gradient mode. The quantification of target compounds was using a selective ionization recording at m/z 425.5 for benazepril, m/z 397.5 for benzeprilat and m/z 288.3 for rutaecarpine. The correlation coefficients of the calibration curves were better than 0.992 (n = 6), in the range of 6.67-666.67 ng/ml for benazepril and benazeprilat. The inter- and intra-day accuracy, precision, linear range had been investigated in detail. The method can be used to assess the bioavailability and pharmacokinetics of the drug.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / blood*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacokinetics
  • Benzazepines / blood*
  • Benzazepines / pharmacokinetics
  • Biological Availability
  • Calibration
  • Chromatography, High Pressure Liquid / methods*
  • Humans
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectrometry, Mass, Electrospray Ionization / methods*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Benzazepines
  • benazeprilat
  • benazepril